The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI).
T. M. Ortiz
Consultant or Advisory Role - Pfizer (U)
V. A. Joshi
Consultant or Advisory Role - KEW Group
S. Heon
No relevant relationships to disclose
M. Butaney
No relevant relationships to disclose
L. Chen
No relevant relationships to disclose
D. M. Jackman
Consultant or Advisory Role - Foundation Medicine
D. J. Kwiatkowski
No relevant relationships to disclose
N. I. Lindeman
No relevant relationships to disclose
P. A. Janne
Consultant or Advisory Role - Abbott Laboratories; AstraZeneca (U); Boehringer Ingelheim; Genentech; Pfizer (U); Roche
Stock Ownership - GATEKEEPER Pharmaceuticals
Other Remuneration - Genzyme
B. E. Johnson
Stock Ownership - KEW Group
Other Remuneration - Patent on EGFR testing